The study evaluates the efficacy of VDPHL01 in addressing mild-to-moderate pattern hair loss across both male and female cohorts. While the firm focuses on these specific trial results during its upcoming briefing, the drug has already advanced into phase 3 development. Market reaction remained measured ahead of the presentation, with shares edging up 1% to $111.27 in after-hours trading.
In section Market Quotes
Veradermics Previews Phase 2 Data for Hair Loss Treatment
Investors will turn their attention to Veradermics on Wednesday morning as the biopharmaceutical firm prepares to disclose findings from the female treatment arms of its phase 2 study. The company plans to detail performance metrics for VDPHL01, an extended-release version of minoxidil, during an 8 a.m. conference call.
Comments (0)
No comments yet. Be the first!